Press release Communiqué de presse
Press release Communiqué de presse
March 3, 2011 3 March, 2011
Sernova To Present Cell Pouch System™ Research Results At Transplantation Conference
Source: Sernova Corp
March 3, 2011, 6:00 a.m. EST
LONDON, ONTARIO--(Marketwire - March 3, 2011) - Sernova Corp. (TSX VENTURE:SVA) is pleased to announce the Company will present results of preclinical studies with its Cell Pouch System(TM), at the Canadian Society of Transplantation 2011 Annual Scientific Conference at Mt-Tremblant, Quebec, Canada held March 2-5.
The conference brings together eminent scientists and clinicians in the cell and organ transplantation field from across Canada and around the world. Sernova will be making three poster presentations entitled:
"The establishment of a stringent large animal model of insulin-dependent diabetes"
"A subcutaneous Cell Pouch(TM) as an alternative to intraportal infusion of islets of Langerhans to restore carbohydrate control in the diabetic recipient," and
"Islets transplanted into a subcutaneous Cell Pouch(TM) demonstrate long-term efficacy measured by C- peptide."
"The conference provides a venue to discuss the attributes of Sernova's novel Cell Pouch System(TM) as an alternate site for insulin-producing islet transplantation and its potential for additional cellular therapies with leaders from the medical transplantation community," stated Delfina Siroen, Sernova's Research and Development Head.
The Cell Pouch System(TM) is a proprietary medical device which may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels. Based on previous pre-clinical research, the Cell Pouch System(TM) becomes a vascularised organ-like endocrine structure when placed in the body, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova has conducted efficacy studies in small and large animal models of diabetes and shown the device with insulin-producing islets to control blood glucose levels long-term without the need for daily insulin injections. Sernova believes the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.
According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.
Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.
For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 firstname.lastname@example.org www.sernova.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.